- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | Damora Therapeutics, Inc.: Damora Announces Redomestication from Delaware to Cayman Islands | 180 | GlobeNewswire (Europe) | BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders... ► Artikel lesen | |
| DAMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14:06 | Damora Therapeutics completes redomestication to Cayman Islands | 1 | Investing.com | ||
| 01.07. | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.06. | Damora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | TD Cowen initiates Damora Therapeutics stock rating at Buy | 2 | Investing.com | ||
| 12.05. | Galecto GAAP EPS of -$0.62 misses by $0.23 | 2 | Seeking Alpha | ||
| 12.05. | Damora Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.05. | Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer | 2 | Insider Monkey | ||
| 04.05. | Damora Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.05. | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.04. | RBC initiates Damora Therapeutics stock at Outperform, $40 target | 1 | Investing.com | ||
| 20.04. | Damora Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 23.03. | Damora Therapeutics: Aktie legt nach Ernennung neuer CEO deutlich zu | 5 | Investing.com Deutsch | ||
| 23.03. | Damora Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.03. | Damora Therapeutics appoints Jennifer Jarrett as CEO | 1 | Seeking Alpha | ||
| 23.03. | Damora names Jennifer Jarrett CEO, adds two board members | 1 | Investing.com | ||
| 23.03. | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | 727 | GlobeNewswire (Europe) | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| 20.03. | Leerink cuts Damora Therapeutics stock price target to $55 on timing | 2 | Investing.com | ||
| 20.03. | Damora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,75 | -0,68 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| EVOTEC | 3,540 | +2,25 % | EVOTEC SE zeigt strukturelle Stärke | ||
| AMGEN | 325,00 | +0,06 % | After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset | ||
| VIKING THERAPEUTICS | 30,850 | -2,99 % | Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock? | ||
| DEFENCE THERAPEUTICS | 0,255 | -6,25 % | Defence Therapeutics Inc.: Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform | Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| ABIVAX | 120,10 | +0,17 % | Abivax-Aktie: Analysten erhöhen Prognosen - diese Woche Übernahmeknall? | Die Abivax-Aktie bleibt einer der spannendsten Biotech-Werte des Jahres. Nachdem Reuters zuletzt bestätigt hatte, dass der französische Wirkstoffentwickler mit mehreren Interessenten über eine mögliche... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,313 | -3,69 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| IBIO | 1,301 | +9,79 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 62,50 | +0,19 % | This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | ||
| ADAPTIVE BIOTECHNOLOGIES | 19,805 | +2,46 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| CYBIN | 6,070 | -1,30 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| VOYAGER THERAPEUTICS | 2,674 | -3,74 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| CAPRICOR | 16,855 | +0,75 % | Cantor Fitzgerald reiterates Overweight on Capricor stock at $62 | ||
| HELIX BIOPHARMA | 0,585 | +2,63 % | Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development | ||
| MEREO BIOPHARMA | 0,274 | -2,14 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
DAMORA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,040 (+3,44 %) liegt der Kurs bei 31,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.